Lack of Mutations inEGFRin Gastroenteropancreatic Neuroendocrine Tumors
Authors:
- Judith A. GilbertJGJudith A. Gilbert
- Ricardo V. LloydRLRicardo V. Lloyd
- Matthew M. AmesMAMatthew M. Ames
- 14 July 2005
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (2) , 209-210
Abstract
To the Editor: Lynch et al.1 and Paez et al.2 correlated the presence of somatic mutations in the tyrosine kinase domain of the gene that encodes the epidermal growth factor receptor (EGFR) with responsiveness to gefitinib in non–small-cell lung carcinoma. Neuroendocrine differentiation is present in a substantial number of gastroenteropancreatic neuroendocrine tumors,3 and EGFR expression occurs in such tumors.4 We sought EGFR-activating mutations in a series of rare gastroenteropancreatic neuroendocrine cancers. DNA was isolated from flash-frozen specimens of carcinoid and pancreatic endocrine tumors; EGFR exons 18, 19, and 21 were amplified by the polymerase chain reaction with primers . . .Keywords
This publication has 4 references indexed in Scilit:
- Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapyHistopathology, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)British Journal of Cancer, 2003